Healthcare / BiotechnologyToronto
$1.52
-0.04 (-2.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-5.5M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$116M
P/E
N/A
•EV/EBITDA
N/A
•ROE
10293.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.3M · FCF $-5.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-9.3M | $-9.3M | $-6.3M | $-6.6M | $-8.0M |
| EBITDA | $-9.2M | $-9.2M | $-6.3M | $-6.5M | $-9.4M |
| EPS | -0.21 | -0.21 | -0.16 | -0.20 | — |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 7.74 | -2.59 |
| Current Ratio | 0.04 | 0.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.2M | $-5.2M | $-5.5M | $-6.5M | $-9.3M |
| Returns | |||||
| ROE | 10293.3% | 10293.3% | 744.4% | -2057.4% | 577.0% |
| Valuation | |||||
| P/B | — | — | — | 84.35 | — |
| Growth & Yield | |||||
| EPS Growth | -31.2% | -31.2% | 20.0% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+65.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.21
Residual
+65.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.